Rockwell Medical, Inc. to Present at Aegis Virtual Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rockwell Medical, a biopharmaceutical company specializing in iron deficiency treatments, will present at the Aegis Virtual Conference on February 23, 2022, from 1:30 to 2:00 PM ET. The company focuses on innovative therapies including its Ferric Pyrophosphate Citrate (FPC) platform, targeting iron deficiency in various patient populations, particularly those on hemodialysis. Recordings of this presentation will be available on their website from February 23 to 25, 2022. Rockwell Medical is also a leading supplier of hemodialysis concentrates in the U.S.
Details
News Market Reaction – RMTI
The recorded move for RMTI in the trading session of this news was +2.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at Aegis Virtual Conference, on Wednesday, February 23rd at 1:30 - 2:00 PM ET.
A recording of the presentation will be posted to the Rockwell Medical website after the conference. The presentation will also be available by request to Aegis from February 23rd to 25th, 2022. To access the event, please download and import the following iCalendar (.ics) files to your calendar system: Aegis Virtual Conference Calendar.
About Rockwell Medical
Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com
CONTACTS
Investors:
Argot Partners
212.600.1902
Rockwell@argotpartners.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.